Hospitals with greater reductions in readmissions rates are no more likely to increase their observation-service use than other hospitals, according to a study reported today in the New England Journal of Medicine. The study examines readmission and observation-service rates before, during and after implementation of the Affordable Care Act and its Hospital Readmissions Reduction Program. “Within hospitals, there was no significant association between changes in observation-service use and changes in readmission rates after implementation of the ACA,” the authors write. The study also found that readmission rates were falling before ACA implementation, declined more quickly after implementation and then at a slower rate after HRRP penalties were initiated. “This study from Department of Health and Human Services researchers shows America’s hospitals have reduced avoidable readmissions and continue to improve,” said AHA President and CEO Rick Pollack. “It also disproves the notion that the reduction in readmissions has led to an increase in observation stays, instead attributing that increase to the overzealous Recovery Audit Contractors who second-guess physician judgment.”

Related News Articles

Headline
Hartford HealthCare in Hartford, Conn., will receive the 2025 AHA Quest for Quality Prize as a result of their sweeping transformation over the past decade —…
Headline
A Q&A in the July edition of AHA Trustee Insights features leaders from Winchester Hospital in Massachusetts discussing the importance of board members…
Headline
To help hospitals across the country improve sepsis care, the Centers for Disease Control and Prevention created the Hospital Sepsis Program Core Elements,…
Headline
The Joint Commission June 30 announced a new, streamlined process that removes 714 requirements from its hospital accreditation program. The new program,…
Headline
AHA President and CEO Rick Pollack explains how hospitals have made meaningful progress in patient safety and delivering high-quality care, in a column…
Headline
A 60-day appeal window has passed for the Food and Drug Administration to appeal a federal court ruling that invalidated its final rule to regulate laboratory-…